Linezolid Powder, For Suspension
Product Images NDC 0054-0319

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Linezolid (NDC 0054-0319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure

Chemical structure of linezolid, the active ingredient in the prescription drug Linezolid. The diagram shows the molecular arrangement of atoms and bonds characteristic to linezolid.*

FDA Label Image

Fpl-bl-10mgper5ml-150ml-02.jpg (Fpl Bl 10mgper5ml 150ml 02)

Linezolid for Oral Suspension 100 mg/5 mL powder for suspension, oral route, in a 150 mL bottle when constituted. The label includes dosage instructions, storage conditions, and handling warnings. Distributed by Hikma Pharmaceuticals USA Inc. The label also features a barcode and NDC 0054-0319-50.*

FDA Label Image

Image 01

A line graph showing the plasma concentration of linezolid (mcg/mL) over time (hours) after a 600 mg oral dose administered every 12 hours. The y-axis represents plasma concentration, from 0 to 28 mcg/mL, and the x-axis represents time, from 0 to 12 hours. Data points with error bars illustrate the concentration trend, peaking around 1 hour and gradually decreasing over 12 hours.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.